Health
Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name TYZAVAN™ (Vancomycin Injection, USP), by the US Food and Drug Administration (FDA).
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"Ready-to-infuse sepsis therapy marks new advancement in time-critical treatment","length":79,"tagName":"p"},{"type":"text","content":"LONDON, July 2, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name TYZAVAN™ (Vancomycin Injection, USP), by the US Food and Drug Administration (FDA).","length":344,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Hikma Pharmaceuticals USA Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Hikma Pharmaceuticals USA Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":108,"url":"https://media.zenfs.com/en/prnewswire.com/fcdee251665d184651b9926f5e9abe51"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/brP0E8SqJTDAbtPocMJv2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fcdee251665d184651b9926f5e9abe51","width":400,"height":108}},"href":"https://mma.prnewswire.com/media/1165956/Hikma_Primary_Coral_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"TYZAVAN™ is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved: (i) septicemia; (ii) infective endocarditis; (iii) skin and skin structure infections; (iv) bone infections; and (v) lower respiratory tract infections.","length":378,"tagName":"p"},{"type":"text","content":"The name TYZAVAN™ stands for "time-saving vancomycin," reflecting its purpose: delivering timely, simplified treatment when every minute counts. TYZAVAN™ is the only FDA-approved vancomycin product commercially available for all patients that is available at room temperature and requires no compounding, thawing, activation or dilution—reducing preparation steps and supporting faster treatment1.","length":422,"tagName":"p"},{"type":"text","content":"According to the Sepsis Alliance, someone in the U.S. is diagnosed with sepsis every 20 seconds, and a sepsis-related death occurs every two minutes.2 Sepsis is a leading cause of death and hospitalization, often requiring rapid antibiotic administ...